Jun 2026 (Q2 FY26) — Aug 11, 2026
DiaMedica Therapeutics Q2 FY26 — Advancing DM-19 Programs in Pregnancy and Stroke
Read the full callDiaMedica Therapeutics (DMAC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
DiaMedica Therapeutics earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -10.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$8.04 +4.96% · +$0.38
Performance +17.4% 1Y
1Y: $6.85 on 14 Oct 2025 → $8.04. High $9.39 (12 Dec 2025), low $5.33 (10 Jun 2026).
- Previous close
- $7.66
- 52-week range
- $5.33 – $9.39
- One year
- +14.04%
Overview
- Symbol
- DMAC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
DiaMedica Therapeutics earnings calls (DMAC)
Financials
What the filings say
Net profit, year on year: −32% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -7 | -8 | -8 | -8 | -9 | -9 | -10 | -10 |
| Other income | 1 | — | — | 0 | 0 | 0 | — | — |
| Profit before tax | -6 | -8 | -8 | -8 | -9 | -9 | -10 | -10 |
| Tax rate | −0.1% | −0.1% | −0.1% | −0.1% | −0.1% | −0.1% | −0.1% | −0.1% |
| Net profit | -6 | -8 | -8 | -8 | -9 | -9 | -10 | -10 |
| EPS ($ per share) | -0.15 | — | -0.18 | -0.18 | -0.17 | — | -0.19 | -0.19 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -46 | -57 | -69 | -83 | -96 | -116 | -140 | -173 |
| Total liabilities | 1 | 1 | 2 | 2 | 3 | 3 | 6 | 5 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | — | 4 | 20 | 40 | 29 | 48 | 41 | 44 |
| Total assets | 18 | 9 | 28 | 46 | 34 | 54 | 46 | 61 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6 | -9 | -9 | -12 | -12 | -19 | -22 | -29 |
| Cash from investing | -0 | -4 | -16 | -21 | 12 | -18 | 9 | -2 |
| Cash from financing | 21 | 0 | 29 | 30 | -0 | 37 | 12 | 44 |
| Net cash flow | — | -13 | 4 | -3 | 0 | -0 | -2 | 13 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | -6 | -9 | -9 | -12 | -12 | -19 | -22 | -29 |
Insider filings
12 filings between Nov 17, 2025 and Aug 10, 2026.
Open market
decisions to buy or sellPurchases
$7.63M
7 purchases by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 4
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| STAHLBERG JAN | $7.63M | — | Nov 25, 2025 |
Latest filings (32)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 10, 2026 | Pauls Dietrich John President & CEO | Award | 60,200 | $0 |
| Jan 2, 2026 | Giuffre Randall Michael Director | Award | 6,175 | $52.0K |
| Jan 2, 2026 | Parsons James T. Director | Award | 10,095 | $85.0K |
| Jan 2, 2026 | Semba Charles Pauling Director | Award | 3,355 | $28.2K |
| Nov 25, 2025 | STAHLBERG JAN 10% owner | Purchase | 73,099 | $626.8K |
| Nov 24, 2025 | STAHLBERG JAN 10% owner | Purchase | 40,253 | $317.7K |
| Nov 21, 2025 | STAHLBERG JAN 10% owner | Purchase | 208,872 | $1.55M |
| Nov 21, 2025 | Parsons James T. Director | Option exercise | 12,000 | $26.4K |
| Nov 20, 2025 | STAHLBERG JAN 10% owner | Purchase | 128,426 | $951.2K |
| Nov 19, 2025 | STAHLBERG JAN 10% owner | Purchase | 240,352 | $1.73M |
| Nov 18, 2025 | STAHLBERG JAN 10% owner | Purchase | 182,882 | $1.23M |
| Nov 17, 2025 | STAHLBERG JAN 10% owner | Purchase | 187,393 | $1.22M |
| Aug 27, 2025 | STAHLBERG JAN 10% owner | Purchase | 50,772 | $304.6K |
| Aug 26, 2025 | STAHLBERG JAN 10% owner | Purchase | 59,648 | $357.9K |
| Aug 25, 2025 | STAHLBERG JAN 10% owner | Purchase | 338,265 | $2.03M |
| Aug 22, 2025 | STAHLBERG JAN 10% owner | Purchase | 59,788 | $356.6K |
| Aug 21, 2025 | STAHLBERG JAN 10% owner | Purchase | 48,172 | $287.0K |
| Aug 20, 2025 | STAHLBERG JAN 10% owner | Purchase | 71,107 | $416.5K |
| Aug 15, 2025 | STAHLBERG JAN 10% owner | Purchase | 8,233 | $49.4K |
| Aug 14, 2025 | STAHLBERG JAN 10% owner | Purchase | 70,414 | $421.9K |
| Aug 13, 2025 | STAHLBERG JAN 10% owner | Purchase | 293,601 | $1.73M |
| Jul 23, 2025 | Von Koch Thomas 10% owner | Purchase | 2,857,142 | $10.00M |
| Jul 23, 2025 | STAHLBERG JAN 10% owner | Purchase | 1,542,857 | $5.40M |
| Jul 23, 2025 | JACINTO RICHARD II 10% owner | Purchase | 400,000 | $1.40M |
| Apr 7, 2025 | Pilnik Richard D. Director | Option exercise | 24,000 | $50.6K |
| Feb 13, 2025 | Giuffre Randall Michael Director | Option exercise | 12,000 | $25.3K |
| Feb 13, 2025 | Giuffre Randall Michael Director | Option exercise | 5,000 | $18.3K |
| Jan 2, 2025 | Semba Charles Pauling Director | Award | 5,290 | $28.2K |
| Jan 2, 2025 | Pilnik Richard D. Director | Award | 10,393 | $55.5K |
| Jan 2, 2025 | Kuntz Richard Director | Award | 9,925 | $53.0K |
| Jan 2, 2025 | Giuffre Randall Michael Director | Award | 10,861 | $58.0K |
| Jan 2, 2025 | Parsons James T. Director | Award | 15,917 | $85.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for DiaMedica Therapeutics Inc.
Free account. Everything above stays public.
Write why you follow DiaMedica Therapeutics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading